Cefizoxime: Difference between revisions
(→Pharmacology: edited half life, excretion, mechanism of action) |
|||
Line 29: | Line 29: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 1.6 - 1.9/hr | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: urine, as unchanged drug | ||
*Mechanism of Action: | *Mechanism of Action: arrests bacterial growth by binding to one or more penicillin binding proteins | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== |
Revision as of 01:17, 12 October 2017
General
- Type: 3rd generation cephalosporin (Discontinued)
- Dosage Forms: powder for injection
- Dosage Strengths: 500mg, 1g, 2g, 10g
- Routes of Administration: IV, IM
- Common Trade Names: Cefizox
Adult Dosing
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 1.6 - 1.9/hr
- Metabolism:
- Excretion: urine, as unchanged drug
- Mechanism of Action: arrests bacterial growth by binding to one or more penicillin binding proteins
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014